DSpace Repository

CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application

Show simple item record

dc.contributor.author Winkler, B.Sophia
dc.contributor.author Oltmer, Franziska
dc.contributor.author Richter, Julia
dc.contributor.author Bischof, Joachim
dc.contributor.author Xu, Pengfei
dc.contributor.author Burster, Timo
dc.contributor.author Leithäuser, Frank
dc.contributor.author Knippschild, Uwe
dc.date.accessioned 2018-08-20T09:10:02Z
dc.date.available 2018-08-20T09:10:02Z
dc.date.issued 2015-02-20
dc.identifier.citation Winkler, B. S., Oltmer, F., Richter, J., Bischof, J., Xu, P., Burster, T., L00eithäuser, F. & Knippschild, U. 2015. CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application. Frontiers in Cell and Developmental Biology. 3, p. 9 en_US
dc.identifier.uri http://nur.nu.edu.kz/handle/123456789/3390
dc.description.abstract The prognosis of lymphoid neoplasms has improved considerably during the last decades. However, treatment response for some lymphoid neoplasms is still poor, indicating the need for new therapeutic approaches. One promising new strategy is the inhibition of kinases regulating key signal transduction pathways, which are of central importance in tumorigenesis. Kinases of the CK1 family may represent an attractive drug target since CK1 expression and/or activity are associated with the pathogenesis of malignant diseases. Over the last years efforts were taken to develop highly potent and selective CK1-specific inhibitor compounds and their therapeutic potential has now to be proved in pre-clinical trials. Therefore, we analyzed expression and mutational status of CK1δ in several cell lines representing established lymphoma entities, and also measured the mRNA expression level in primary lymphoma tissue as well as in non-neoplastic blood cells. For a selection of lymphoma cell lines we furthermore determined CK1δ kinase activity and demonstrated therapeutic potential of CK1-specific inhibitors as a putative therapeutic option in the treatment of lymphoid neoplasms en_US
dc.language.iso en en_US
dc.publisher Frontiers in Cell and Developmental Biology en_US
dc.rights Attribution-NonCommercial-ShareAlike 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/3.0/us/ *
dc.subject CK1 en_US
dc.subject lymphoma en_US
dc.subject therapy en_US
dc.subject inhibitor en_US
dc.subject mutationanalysis en_US
dc.subject cellcycle en_US
dc.title CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application en_US
dc.type Article en_US
workflow.import.source science


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States

Video Guide

Submission guideSubmission guide

Submit your materials for publication to

NU Repository Drive

Browse

My Account

Statistics